Skip to main content

Advertisement

Table 1 Characteristics of clinical trials included in the meta-analysis

From: The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

Study (phase) First author Cancer type Treatment arm
(No. of patients)
Control arm 1
(No. of patients)
Control arm 2
(No. of patients)
Refs.
Alliance A091401
Phase 2
D’Angelo SP Sarcoma Nivolumab plus
Ipilimumab (42)
Nivolumab (43)   [29]
CheckMate 032
Phase 1/2
Janjigian YY Esophagogastric Cancer Nivolumab plus
Ipilimumab (101)
Nivolumab (59)   [13]
CheckMate 067
Phase 3
Hodi FS Melanoma Nivolumab plus
Ipilimumab (314)
Nivolumab (316) Ipilimumab (315) [30]
CheckMate 069
Phase 2
Hodi FS Melanoma Nivolumab plus
Ipilimumab (95)
Ipilimumab (47)   [31]
CheckMate 214
Phase 3
Motzer RJ Renal-Cell Carcinoma Nivolumab plus
Ipilimumab (550)
Sunitinib (546)   [32]
CheckMate 227a
Phase 3
Hellmann MD NSCLC Nivolumab plus
Ipilimumab (583)
Nivolumab (396) Chemotherapy (583) [33]
NCT02374242b
Phase 2
Long GV Melanoma Nivolumab plus
Ipilimumab (35)
Nivolumab (31)   [34]
Checkmate 143c
Phase 1
Omuro A Glioblastoma Nivolumab plus
Ipilimumab (10)
Nivolumab (10)   [35]
  1. NSCLC non-small-cell lung cancer
  2. a583, 396, and 583 patients were assigned to Nivolumab plus Ipilimumab group, Nivolumab group, and Chemotherapy group in CheckMate 227 totally. However, the difference comparison among three groups was just conducted in patients harboring at least 10 mutations per megabase
  3. bNCT02374242 contained three cohorts: Cohort A (Nivolumab plus Ipilimumab, n = 35), B (Nivolumab, n = 25), and C (Nivolumab, n = 6). Among three cohorts, Cohort A and B consisted of patients with the same diagnosis and treatment. 60 patients were randomly assigned to Cohort A and B while 6 patients were selected to Cohort C. Therefore, the following analysis was based on Cohort A and B
  4. cCheckmate 143 consisted of three cohorts: Cohort A (Nivolumab, n = 10), Cohort B (Nivolumab plus Ipilimumab, n = 10), and Cohort C (Nivolumab plus Ipilimumab, n = 20). 20 glioblastoma patients were 1:1 randomly assigned to Cohort A and B while 20 patients were allocated to Cohort C. Thus, the following analysis was based on Cohort A and B